Summit Therapeutics (LON:SUMM) released its earnings results on Wednesday. The company reported GBX (3) (($0.04)) earnings per share for the quarter, topping analysts’ consensus estimates of GBX (10.10) (($0.14)) by GBX 7.10 ($0.10), Bloomberg Earnings reports. The firm had revenue of £173 million during the quarter.

Shares of Summit Therapeutics (SUMM) opened at GBX 180 ($2.42) on Wednesday. Summit Therapeutics has a 52-week low of GBX 138.14 ($1.86) and a 52-week high of GBX 269.70 ($3.63).

SUMM has been the subject of a number of recent research reports. reiterated a “corporate” rating on shares of Summit Therapeutics in a research report on Tuesday, November 7th. N+1 Singer reiterated a “corporate” rating on shares of Summit Therapeutics in a research report on Tuesday, November 7th.

WARNING: “Summit Therapeutics (SUMM) Issues Earnings Results” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/06/summit-therapeutics-summ-issues-earnings-results.html.

About Summit Therapeutics

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.